摘要
目的：观察慢性阻塞性肺疾病（COPD）稳定期脾肾阳虚证患者应用喘可治注射液穴位注射治疗配合护理健康教育的临床疗效。方法采用前瞻性研究方法，选择2014年2至4月在杭州市第三人民医院和浙江省新华医院诊治的118例COPD稳定期脾肾阳虚证患者，按随机数字表法分为试验组60例和对照组58例。两组患者均给予常规治疗〔按COPD全球倡议（GOLD）采用氧疗、支气管扩张剂、糖皮质激素、康复治疗〕；试验组同时穴位注射喘可治注射液，每日1次，疗程12周，并配合相应的健康教育。定期随访9个月，比较两组患者的肺功能、生活质量和预后。结果12周后，试验组1秒用力呼气容积（FEV1）、FEV1/用力肺活量（FVC）、每分钟最大通气量（MVV）均显著高于对照组〔FEV1（L）为1.57±0.42比1.35±0.35，FEV1/FVC为（58.62±4.56）%比（50.36±4.35）%，MVV（L/min）为60.62±7.56比56.95±6.33，均P＜0.05〕。试验组COPD生活质量评价表（QLICD-COPD）躯体功能、心理功能、社会功能、呼吸特异模块的评分均显著高于对照组（分：总分为74.69±8.92比68.62±8.95，躯体功能为74.16±8.55比66.31±7.15，心理功能为78.69±9.79比72.64±8.45，社会功能为75.45±6.75比70.36±6.12，呼吸特异模块为67.52±6.33比61.36±6.17，均P＜0.05）；Barthel指数评分也显著高于对照组（分：75.41±9.24比68.43±7.95，P＜0.05）。随访9个月内，试验组COPD急性发作的发生率均显著低于对照组〔5.00%（3/60）比17.24%（10/58），P＜0.05〕；患者的再入院率也明显少于对照组〔1.67%（1/60）比12.07%（7/58），P＜0.05〕。结论喘可治注射液穴位注射配合健康教育对COPD稳定期脾肾阳虚证患者有良好的临床疗效，值得推广。
Objective To observe the clinical efficacy of Chuankezhi acupoint injection combined with nursing health care education for treatment of patients with chronic obstructive pulmonary disease （COPD） at stable stage complicated with spleen kidney deficiency syndrome.Methods A prospective study was conducted. 118 patients with stable COPD and spleen kidney yang deficiency syndrome admitted to Hangzhou Third People＇s Hospital and Zhejiang Xinhua Hospital from February to April 2014 were enrolled, and they were divided into an experimental group （60 cases） and a control group （58 cases） according to the random number table. Both groups were given conventional treatment [including oxygen therapy, bronchodilators, corticosteroids, rehabilitation therapy in accord with the Global Initiative COPD （GOLD）]. Simultaneously, in the experimental group, Chuankezhi acupoint injection was additionally given, once daily for 12 weeks, and appropriate corresponding health education was mentioned. The lung function, quality of life and prognoses of the patients were regularly followed up for 9 months and compared between the two groups.Results After 12 weeks, one second forced expiratory volume （FEV1）, FEV1/forced vital capacity （FVC） and maximum voluntary ventilation （MVV） per minute in the experimental group were significantly higher than those in control group [FEV1 （L）： 1.57±0.42 vs. 1.35±0.35, FEV1/FVC： （58.62±4.56）% vs. （50.36±4.35）%, MVV （L/min）： 60.62±7.56 vs. 56.95±6.33, allP 〈 0.05]. The quality of life evaluation form for COPD （QLICD-COPD） was used to evaluate the physical function, psychological function, social function and specific modules scores, showing that the above items in the experimental group were significantly higher than those in control group （total score： 74.69±8.92 vs. 68.62±8.95, physical function score： 74.16±8.55 vs. 66.31±7.15, mental function score： 78.69±9.79 vs. 72.64±8.45, social function score： 75.45±6.75 vs. 70.36±6.1
出处
《中国中西医结合急救杂志》
CAS
北大核心
2015年第6期565-568,共4页
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
基金
国家自然科学基金青年基金资助项目（81302935）
浙江省杭州市卫生科技计划一般项目（2013810）
关键词
肺疾病
阻塞性
慢性
稳定期
穴位注射
健康教育
肾阳虚证
喘可治注射液
Chronic obstructive pulmonary disease
Stable stage
Acupoint injection
Health education
Kidney yang deficiency syndrome
Chuankezhi injection
